Last reviewed · How we verify
Aspegic ® (Aspirin)
Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to decrease inflammation, pain, and platelet aggregation.
Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to decrease inflammation, pain, and platelet aggregation. Used for Acute myocardial infarction prevention and secondary prevention, Ischemic stroke prevention, Transient ischemic attack (TIA) prevention.
At a glance
| Generic name | Aspegic ® (Aspirin) |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent |
| Target | Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular; Pain management; Inflammation |
| Phase | Phase 3 |
Mechanism of action
Aspirin acetylates serine residues on COX-1 and COX-2 enzymes, permanently blocking their catalytic activity. This prevents the synthesis of prostaglandins (which mediate inflammation and pain) and thromboxane A2 (which promotes platelet clumping). The antiplatelet effect is particularly important at low doses, where COX-1 inhibition in platelets predominates, making aspirin useful for cardiovascular protection.
Approved indications
- Acute myocardial infarction prevention and secondary prevention
- Ischemic stroke prevention
- Transient ischemic attack (TIA) prevention
- Mild to moderate pain and fever
- Rheumatoid arthritis and other inflammatory conditions
Common side effects
- Gastrointestinal bleeding or ulceration
- Dyspepsia
- Nausea
- Hemorrhage (minor)
- Hypersensitivity reactions (in aspirin-sensitive patients)
Key clinical trials
- Prevention of Maternal and Perinatal Complications by Enoxaparin in Women With Previous Severe Preeclampsia (PHASE3)
- BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aspegic ® (Aspirin) CI brief — competitive landscape report
- Aspegic ® (Aspirin) updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI